Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osocimab Safety in ESRD Patients on Hemodialysis
NCT04523220Phase 2Completed
- Sponsor
- Bayer
- Start
- Aug 2020
- Primary completion
- Dec 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 2 trial of osocimab in thromboembolism, sponsored by Bayer. Started Aug 2020; status: completed.
02
Drugs
osocimab
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04523220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523220.